GSK and ViiV Healthcare Use $130 Million Priority Review Voucher to Expedite HIV Therapy

Drug Industry Daily
A A
GlaxoSmithKline and ViiV Healthcare redeemed a priority review voucher for their application for a single-tablet antiretroviral regimen of Tivicay (dolutegravir) and Edurant (rilpivirine) for maintenance treatment of HIV-1 infections. The voucher allows for an expedited six-month review — cutting four months from the standard review.

To View This Article:

Login

Subscribe To Drug Industry Daily